The SANEMUS team supervises a biotech start-up in attracting venture capital, which has developed a proprietary technology platform for the encapsulation of nucleid acids (siRNA, mRNA) as well as low molecular compounds. The goal is the development of new RNA drugs in cancer therapy and the therapy of genetic defects. Talks are currently taking place with institutional VCs. The goal ist the closing of Series A round in Q1/Q2 2018. If you are interested in participating, please contact us.